Key challenges for drugs in clinical development for cholangiocarcinoma
- PMID: 33530767
- PMCID: PMC11994244
- DOI: 10.1080/13543784.2021.1880565
Key challenges for drugs in clinical development for cholangiocarcinoma
Similar articles
-
Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs.Expert Opin Investig Drugs. 2021 Jul;30(7):675-679. doi: 10.1080/13543784.2021.1916912. Epub 2021 May 2. Expert Opin Investig Drugs. 2021. PMID: 33934687 No abstract available.
-
The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs.Expert Opin Investig Drugs. 2021 Apr;30(4):281-284. doi: 10.1080/13543784.2021.1849139. Epub 2020 Nov 23. Expert Opin Investig Drugs. 2021. PMID: 33228417 No abstract available.
-
Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.Expert Rev Anticancer Ther. 2011 Apr;11(4):589-600. doi: 10.1586/era.11.17. Expert Rev Anticancer Ther. 2011. PMID: 21504326 Review.
-
Cholangiocarcinoma: shedding light on the most promising drugs in clinical development.Expert Opin Investig Drugs. 2021 Apr;30(4):419-427. doi: 10.1080/13543784.2021.1897103. Epub 2021 Mar 7. Expert Opin Investig Drugs. 2021. PMID: 33645382 Review.
-
Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma.Surg Oncol Clin N Am. 2019 Oct;28(4):695-715. doi: 10.1016/j.soc.2019.06.015. Surg Oncol Clin N Am. 2019. PMID: 31472914 Review.
Cited by
-
Epidermal growth factor rs4444903 polymorphism and risk of cholangiocarcinoma. A case control study.Clin Exp Hepatol. 2023 Jun;9(2):138-145. doi: 10.5114/ceh.2023.128131. Epub 2023 Jun 30. Clin Exp Hepatol. 2023. PMID: 37502431 Free PMC article.
-
Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach.Cancers (Basel). 2022 Jan 13;14(2):392. doi: 10.3390/cancers14020392. Cancers (Basel). 2022. PMID: 35053557 Free PMC article. Review.
-
An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma.Oncologist. 2022 Oct 1;27(10):884-891. doi: 10.1093/oncolo/oyac139. Oncologist. 2022. PMID: 35925597 Free PMC article.
-
Applications of 3D models in cholangiocarcinoma.Front Oncol. 2025 Jul 31;15:1598552. doi: 10.3389/fonc.2025.1598552. eCollection 2025. Front Oncol. 2025. PMID: 40823086 Free PMC article. Review.
-
Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial.JAMA Oncol. 2023 May 1;9(5):692-699. doi: 10.1001/jamaoncol.2023.0016. JAMA Oncol. 2023. PMID: 36951834 Free PMC article. Clinical Trial.
References
-
- Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–588. - PMC - PubMed
-
•• This is a very comprehensive review of the etiology, biology, and management of cholangiocarcinom, covering the spectrum of basic science to clinical knowledge.
-
- Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71(1):104–114. - PubMed
-
- Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical